Stock Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron cuts top end of eye drug sales forecast

[Reuters] – Regeneron Pharmaceuticals Inc cut the top end of its full-year sales forecast for its blockbuster eye drug and reported a lower-than-expected adjusted quarterly profit, citing higher costs. The company’s … Read . . . → Read More: Stock Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron cuts top end of eye drug sales forecast Similar Articles: Market Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron Announces Upcoming 2014 Investor Conference Presentations Stock Update (NASDAQ:REGN): EYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO) Company Update (NASDAQ:REGN): Regeneron Announces Upcoming 2014 Investor Conference Presentations